We demonstrated that Calebin-A could potentially target TP53, TNF, STAT3, HSP90AA1, PTGS2, HDAC6, ABCB1, CCT2, NR1I2, and GUSB, which are overexpressed in patients with NAFLD. Here, NR1I2 is linked to metabolic dysfunction-associated steatotic liver disease.